Facilitating Antibacterial Drug Development in a Time of Great Need.
暂无分享,去创建一个
J. Woodcock | H. Eichler | M. Cavaleri | L. Borio | E. Cox
[1] V. Fowler,et al. Improving Conduct and Feasibility of Clinical Trials to Evaluate Antibacterial Drugs to Treat Hospital-Acquired Bacterial Pneumonia and Ventilator-Associated Bacterial Pneumonia: Recommendations of the Clinical Trials Transformation Initiative Antibacterial Drug Development Project Team. , 2016, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[2] H. Goossens,et al. Efficient Delivery of Investigational Antibacterial Agents via Sustainable Clinical Trial Networks , 2016, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[3] Y. Schlesinger. Editorial Commentary: Amniocentesis for Detection of Congenital Cytomegalovirus Infection: What Is the Point? , 2016, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[4] S. Burns,et al. Transmission of Hepatitis B Core Antibody and Galactomannan Enzyme Immunoassay Positivity via Immunoglobulin Products: A Comprehensive Analysis. , 2016, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[5] Ronald N. Jones,et al. 10 x '20 Progress--development of new drugs active against gram-negative bacilli: an update from the Infectious Diseases Society of America. , 2013, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[6] Amber Jessup,et al. ANALYTICAL FRAMEWORK FOR EXAMINING THE VALUE OF ANTIBACTERIAL PRODUCTS , 2014 .